- Home
- ARDX
ARDX
Ardelyx Inc.
as 07-26-2024 4:00pm EST
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Upcoming Earnings Alert:
Get ready for potential market movements as Ardelyx Inc. ARDX prepares to release earnings report on 01 Aug 2024.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 1.2B | IPO Year: | 2014 |
| Target Price: | $12.64 | AVG Volume (30 days): | 5.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.16 - $10.13 | Next Earning Date: | 08-01-2024 |
| Revenue: | $159,110,000 | Revenue Growth: | 152.32% |
| Revenue Growth (this year): | 101.33% | Revenue Growth (next year): | 64.54% |
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | ARDX | President & CEO | Jul 15 '24 | Sell | $5.97 | 7,500 | $44,767.50 | 1,260,463 | SEC Form 4 |
| RAAB MICHAEL | ARDX | President & CEO | Jun 28 '24 | Sell | $6.59 | 2,310 | $15,222.90 | 1,267,963 | SEC Form 4 |
| Blanks Robert | ARDX | See Remarks | Jun 21 '24 | Sell | $5.96 | 38,000 | $226,290.00 | 324,331 | SEC Form 4 |
| RAAB MICHAEL | ARDX | President & CEO | Jun 13 '24 | Sell | $6.65 | 35,000 | $232,743.00 | 1,270,273 | SEC Form 4 |
| Williams Laura A | ARDX | Chief Medical Officer | Jun 5 '24 | Sell | $7.12 | 45,000 | $320,580.00 | 422,152 | SEC Form 4 |
| Williams Laura A | ARDX | Chief Medical Officer | Jun 5 '24 | Sell | $7.13 | 100,000 | $712,500.00 | 322,152 | SEC Form 4 |
| Rosenbaum David P. | ARDX | Chief Development Officer | Jun 3 '24 | Sell | $7.00 | 17,872 | $125,104.00 | 158,502 | SEC Form 4 |
| Renz Justin A | ARDX | Chief Financial Officer | May 21 '24 | Sell | $7.81 | 5,167 | $40,359.44 | 300,546 | SEC Form 4 |
| GRAMMER ELIZABETH A | ARDX | See Remarks | May 21 '24 | Sell | $7.81 | 6,927 | $54,106.80 | 199,469 | SEC Form 4 |
| Blanks Robert | ARDX | See Remarks | May 21 '24 | Sell | $7.81 | 4,855 | $37,922.41 | 362,331 | SEC Form 4 |
| Williams Laura A | ARDX | Chief Medical Officer | May 21 '24 | Sell | $7.81 | 4,794 | $37,445.93 | 367,152 | SEC Form 4 |
| Rosenbaum David P. | ARDX | Chief Development Officer | May 21 '24 | Sell | $7.81 | 4,855 | $37,922.41 | 376,479 | SEC Form 4 |
| Rosenbaum David P. | ARDX | Chief Development Officer | May 21 '24 | Sell | $7.81 | 2,198 | $17,168.58 | 176,374 | SEC Form 4 |
| Rodriguez Susan | ARDX | Chief Commercial Officer | May 21 '24 | Sell | $7.81 | 6,703 | $52,357.13 | 449,092 | SEC Form 4 |
| Felsch Robert Ora | ARDX | See Remarks | May 21 '24 | Sell | $7.81 | 3,485 | $27,221.34 | 95,127 | SEC Form 4 |
| RAAB MICHAEL | ARDX | President & CEO | May 21 '24 | Sell | $7.81 | 31,484 | $245,921.52 | 1,277,773 | SEC Form 4 |
| RAAB MICHAEL | ARDX | President & CEO | May 14 '24 | Sell | $7.99 | 3,000 | $23,970.00 | 1,307,933 | SEC Form 4 |
| Felsch Robert Ora | ARDX | See Remarks | May 6 '24 | Sell | $8.81 | 152,988 | $1,347,503.01 | 150,947 | SEC Form 4 |
| Felsch Robert Ora | ARDX | See Remarks | May 6 '24 | Sell | $8.80 | 55,000 | $484,000.00 | 95,947 | SEC Form 4 |
| GRAMMER ELIZABETH A | ARDX | See Remarks | May 6 '24 | Sell | $8.87 | 64,233 | $569,836.64 | 423,697 | SEC Form 4 |
| GRAMMER ELIZABETH A | ARDX | See Remarks | May 6 '24 | Sell | $8.88 | 219,937 | $1,952,380.75 | 203,760 | SEC Form 4 |
| GRAMMER ELIZABETH A | ARDX | See Remarks | May 3 '24 | Sell | $9.00 | 45,000 | $405,000.00 | 267,993 | SEC Form 4 |
| Williams Laura A | ARDX | Chief Medical Officer | May 3 '24 | Sell | $8.35 | 39,949 | $333,574.15 | 370,189 | SEC Form 4 |
| RAAB MICHAEL | ARDX | President & CEO | Apr 29 '24 | Sell | $6.40 | 30,000 | $192,057.00 | 1,310,933 | SEC Form 4 |
| RAAB MICHAEL | ARDX | President & CEO | Apr 15 '24 | Sell | $7.06 | 7,500 | $52,923.75 | 1,310,933 | SEC Form 4 |
Latest Ardelyx Inc. News
ARDX Breaking Stock News: Dive into ARDX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
Pharmaceutical Technology
8 days ago
Ardelyx sues CMS over revamped kidney disease drug payment bundle
MT Newswires
8 days ago
Ardelyx, Groups File Lawsuit Over Dialysis Payment System Coverage
GlobeNewswire
8 days ago
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
GlobeNewswire
9 days ago
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
Zacks
11 days ago
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
MT Newswires
23 days ago
HC Wainwright Adjusts Ardelyx's Price Target to $10 From $13, Keeps Buy Rating
MT Newswires
24 days ago
Wedbush Adjusts Ardelyx's Price Target to $11 From $15, Keeps Outperform Rating
Compare ARDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.